PO.TB04.04 · 肿瘤生物学
用于研究TME并评估抗癌药物的肺癌原位移植模型的开发及其临床前研究应用
Development of a lung cancer orthotopic transplantation model for investigating the TME and evaluating anticancer agents for preclinical studies
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
异位皮下(SC)肿瘤移植模型因其技术简便和易于监测肿瘤而在癌症研究中广泛使用。然而,这些模型无法重现天然肿瘤微环境(TME)。为克服这一局限,我们在小鼠中开发了基于支气管镜的原位(ORT)肺癌模型,并将其TME和药物应答与SC模型进行了比较。使用了三种表达荧光素酶的肺腺癌模型:A549-Luc、RERF-LC-KJ-Luc和LC-58-Luc(一种来源于患者来源异种移植的细胞系,由CIEM建立)。在ORT模型中,于移植前三天通过支气管镜向左肺叶给予3%月桂基-10溶液,随后灌注20 μL含10% Matrigel培养基中的1×10⁶个细胞。SC肿瘤通过皮下注射相同细胞(100 μL含50% Matrigel中的1×10⁶个细胞)建立。通过生物发光(ORT)或卡尺测量(SC)监测肿瘤生长。小鼠接受卡铂(CBDCA,50 mg/kg,腹腔注射,3次给药,间隔5天)和紫杉醇(PTX,15 mg/kg,腹腔注射,5次给药,间隔3天)。还评估了VEGF抑制剂联合化疗。使用150 bp双端NovaSeq进行RNA测序,读段使用TrimGalore、Xenogsort、STAR和RSEM处理。使用MultiNicheNet分析人-鼠相互作用组。CBDCA和PTX在SC和ORT模型中均显示出显著的抗肿瘤效应。在SC肿瘤中,与VEGF抑制剂联合化疗显著减少了mCD31阳性内皮细胞的数量,这与抗血管生成应答一致。相比之下,在ORT肿瘤中未观察到此类效应,凸显了血管应答中TME依赖性差异。RNA测序显示ORT特异性上调表面活性物质基因(SFTPA1、SFTPB和SFTPC),表明肺特异性适应。MultiNicheNet分析揭示了ORT富集的与神经周围浸润和黏附相关的配体-受体对,强调了增强的宿主-肿瘤串扰。该ORT模型能更好地模拟临床TME动态,并能对抗癌药物进行更具转化相关性的评估。
基于支气管镜的ORT肺癌模型重现了生理相关的肿瘤-宿主相互作用和TME依赖性药物应答。通过纳入VEGF抑制剂应答和转录组学分析,与SC模型相比,该模型为评估抗肿瘤药物和改善转化可预测性提供了更好的临床前平台。
查看英文原文 English abstract
Heterotopic subcutaneous (SC) tumor transplantation models are widely used in cancer research owing to their technical simplicity and ease of tumor monitoring. However, these models fail to recapitulate the native tumor microenvironment (TME). To overcome this limitation, we developed a bronchoscopy-based orthotopic (ORT) lung cancer model in mice and compared its TME and drug response with those of the SC model.Three luciferase-expressing lung adenocarcinoma models were used: A549-Luc, RERF-LC-KJ-Luc, and LC-58-Luc (a cell line derived from a patient-derived xenograft, CIEM-established). In the ORT model, 3% lauryl-10 solution was administered via bronchoscopy to the left lung lobule three days prior to transplantation, followed by instillation of 1×10⁵ cells in 20 µL medium containing 10% Matrigel. SC tumors were established by subcutaneous injection of the same cells (1×10⁵ cells in 100 µL with 50% Matrigel). Tumor growth was monitored via bioluminescence (ORT) or caliper measurements (SC). Mice received carboplatin (CBDCA, 50 mg/kg, i.p., 3 doses at 5-day intervals) and paclitaxel (PTX, 15 mg/kg, i.p., 5 doses at 3-day intervals). VEGF inhibitor combination chemotherapy was also evaluated. RNA sequencing was performed using 150 bp paired-end NovaSeq, with the reads processed using TrimGalore, Xenogsort, STAR, and RSEM. The human-mouse interactome was analyzed using MultiNicheNet. CBDCA and PTX showed significant antitumor effects in both SC and ORT models. In the SC tumors, combination chemotherapy with the VEGF inhibitor significantly reduced the number of mCD31-positive endothelial cells, which is consistent with the anti-angiogenic response. By contrast, no such effect was observed in the ORT tumors, highlighting the TME-dependent differences in vascular responses. RNA sequencing showed ORT-specific upregulation of surfactant genes ( SFTPA1 , SFTPB , and SFTPC ), indicating lung-specific adaptation. MultiNicheNet analysis revealed ORT-enriched ligand-receptor pairs linked to perineural invasion and adhesion, underscoring enhanced host-tumor crosstalk. This ORT model better mimics clinical TME dynamics and enables a more translationally relevant evaluation of anticancer agents.
Bronchoscopy-based ORT lung cancer models recapitulate physiologically relevant tumor-host interactions and TME-dependent drug responses. By incorporating VEGF inhibitor response and transcriptomic profiling, this model provides a better preclinical platform for evaluating antitumor agents and improving translational predictability compared with SC models.
利益披露 Disclosure
C. Nishime, None..
E. Nishinaka, None..
H. Satou, None..
T. Imai, None..
M. Komatsu, None..
M. Mochizuki, None..
T. Yamamoto, None..
M. Suzuki, None.